Loading...
Market
Story
FDA-Approved Novartis's Kisqali Shows 28.5% Reduction in Early Breast Cancer Recurrence Risk
Sep 17, 2024, 05:12 PM
Novartis has announced that its breast cancer drug, Kisqali, has shown significant benefits in reducing the risk of recurrence in early breast cancer patients. A new analysis revealed that Kisqali reduces the risk of recurrence by 28.5% in a broad population of patients. The FDA has expanded the approval of Kisqali to include patients with earlier stages of the disease, providing tens of thousands of women access to a drug that could help prevent their cancer from returning. This approval is based on the efficacy and safety results of the NATALEE trial and includes patients with HR+/HER2- stage 2 & 3 breast cancer.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 10,000 • 25%
10,000 - 20,000 • 25%
20,000 - 30,000 • 25%
More than 30,000 • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Launch new competing drug • 25%
Increase marketing for existing drugs • 25%
File a lawsuit or regulatory complaint • 25%
No significant response • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%